Document is current
Any future updates will be listed below
-
Authors
Serota, David P
Feaster, Daniel J.
Bartholomew, Tyler S.
Kapadia, Shashi N.
Gooden, Lauren K.
Murphy, Sean M.
Malik, Subul
Chueng, Teresa A.
Hernandez, Salma
Rodriguez, Allan E.
Alonso, Elizabeth
Horigian, Viviana E.
Walker, Robrina
Matheson, Tim
Moran, Landhing M.
Nelson, C Mindy
Parish, Carrigan
Tookes, Hansel E.
Rio, Carlos Del
Metsch, Lisa R.
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 2 February 2026
First Online: 21 February 2026
Declarations
:
: The study was reviewed and approved by the University of Miami Institutional Review Board (UM; IRB#20221134) which serves as the single IRB for the trial and provides regulatory oversight over all the participating sites.
: Not applicable.
: The current protocol in use is version 4 (2/19/2025). The trial began recruitment on January 5, 2024 and is ongoing at the time of manuscript submission. This research was supported by the National Institute on Drug Abuse under Award Number UG1DA013720. Landhing Moran was substantially involved in UG1DA013720, consistent with her role as Scientific Officer. The views and opinions expressed in this manuscript are those of the authors only and do not necessarily represent the views, official policy or position of the U.S. Department of Health and Human Services or any of its affiliated institutions or agencies.
: ClinicalTrials.gov NCT05688423 ( ). Trial registry name: CTN-0121: Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders (SUD) among Hospitalized Patients. Trial Sponsor: Landhing Moran, PhD, landhing.moran@nih.gov, National Institute on Drug Abuse Clinical Trials Network. Registration date: January 17, 2023. Protocol Version 4.0.
: The authors declare no competing interests.
